Please assess the completion status of the following clinical trial:

Trial Title: Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria :~* A pathologically confirmed diagnosis of malignant melanoma with at least one measurable metastatic lesion with a minimum lesion size of 20 mm, based on radiological assessment (or 10 mm if assessed by spiral computed tomography \[CT\] scan ) as per Response Evaluation Criteria in Solid Tumors (RECIST) criteria (Stages IIIc, IVa, or IVb only, according to the American Joint Committee on Cancer (AJCC) staging system for melanoma). Cutaneous metastasis (assessed by physical examination) must be at least 10 mm. CT scan or magnetic resonance imaging (MRI) is required to rule out brain metastases.~* Patients who received prior treatment for their metastatic disease must have objective evidence of disease progression.~* Aged ≥ 18 years on the day of inclusion~* IRB-approved informed consent form signed~* Able to attend all scheduled visits and to comply with all trial procedures~* For a woman, inability to bear a child or negative serum pregnancy test~* For a woman of child-bearing potential, using an effective method of contraception or abstinence during the study and at least 4 weeks after the last study treatment~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and a life expectancy of at least 6 months.~* Adequate hematologic, hepatic, and renal function (at pre-defined laboratory values).~* Fully recovered from surgery, if applicable.~Exclusion Criteria :~* Receipt of two or more previous therapies for metastatic melanoma.~* Receipt of chemotherapy or another therapy for metastatic melanoma within the last four weeks~* Receipt of adjuvant interferon therapy within the last six months~* Concurrent receipt of radiotherapy for the metastatic disease, unless for palliative purposes~* Participation in another clinical trial within the four weeks preceding the first trial treatment~* Planned participation in another clinical trial during the present trial period~* Known Human Immunodeficiency Virus (HIV) infection or hepatitis B (Ag HBs) or hepatitis C seropositivity~* Presence of active autoimmune disease (excluding vitiligo)~* Systemic hypersensitivity to bovine products or to any of the vaccine components, including egg products or Neomycin (used to prepare the vaccine), or history of a life-threatening reaction to granulocyte-macrophage colony stimulating factor (GM-CSF) or interferon (IFN)-α2b~* Current alcohol or drug addiction that may interfere with the ability to comply with trial procedures~* Significant co-morbid medical conditions, including pre-existing renal disease, cirrhosis, or major depression, which in the estimation of the investigator would preclude safe participation in the study or the accurate interpretation of data.~* A calculated glomerular filtration rate (GFR) \<60 mL/min (based on the Cockroft-Gault formula).~* Previous receipt of a modified canarypox virus (ALVAC)-based vaccine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Study Group 1: ALVAC melanoma vaccine (Type: EXPERIMENTAL): Participants will receive a multi-antigen of modified canarypox virus (ALVAC\[2\]) melanoma vaccine and granulocyte macrophage colony stimulating factor (GM-CSF) every 3 weeks, followed by 4 weeks of high-dose interferon alpha-2b 5 times per week.
- Study Group 2: Interferon alpha-2b (Type: ACTIVE_COMPARATOR): Participants on 4 weeks of high-dose interferon alpha-2b 5 times per week. Participants who showed disease progression after Cycle 1 will be permitted to cross over to Group 1 treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).